Centessa Pharmaceuticals (NASDAQ:CNTA) Issues Quarterly Earnings Results

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) released its earnings results on Monday. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04, Zacks reports.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA traded up $0.08 during mid-day trading on Friday, hitting $14.59. 620,346 shares of the company's stock traded hands, compared to its average volume of 548,232. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company's 50-day moving average is $16.48 and its two-hundred day moving average is $16.41. The company has a market capitalization of $1.92 billion, a P/E ratio of -9.54 and a beta of 1.54.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CNTA shares. Guggenheim reiterated a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.00.

Remove Ads

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares of the company's stock, valued at approximately $1,808,271.85. The trade was a 4.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total value of $163,400.00. Following the completion of the sale, the insider now owns 134,021 shares of the company's stock, valued at approximately $2,189,903.14. This represents a 6.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 260,168 shares of company stock worth $4,309,568. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.